UPCC 07618:A Multicenter Open label Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Recruiting
99 years or below
All
1 Location
Brief description of study
TBD
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
25 May 2021.
Study ID: 831192